News
11 Apr 2014
Kyowa Hakko Kirin Completes Construction of its Biopharmaceutical API Manufacturing Facility in the Takasaki Plant
Kyowa Hakko Kirin Co., Ltd has completed the construction of the HA4 Plant (biopharmaceutical API manufacturing facility) at the Takasaki Plant in April 8, 2014.
The HA4 Plant has been installed as one of the largest bioreactors for recombinant animal cells (12,000 L bioreactor) in Japan, as well as a purification facility with a large column. By utilizing the manufacturing technology of biopharmaceutical products cultivated by the company, the company will realise a larger scale and stable manufacture, and continue to make efforts to provide the market with high-quality pharmaceutical products.
Related News
-
News Ardena forms partnership with RiboPro to improve mRNA-based therapies
Ardena and RiboPro have formed an alliance to boost their respective skills in manufacturing and producing nanoparticle and mRNA-based therapeutics to improve accessibility to this technology in the biotherapeutic landscape. -
News Updated: Samsung Biologics to manufacture Pfizer's biosimilars products
Samsung Biologics agrees to use their biocampus Plant 4 for the manufacture of a line of products from Pfizer. -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Soft capsule technology: modified pea starch as a vegetal origin alternative to gelatin in capsule shell
The latest soft capsule technology from Roquette using modified pea starch as an alternative to gelatin. -
News Your Prescription for Marketing Success: Digital Pharma Marketing Toolkit – Free eBook
Download your FREE pharma marketing eBook to learn why it is so important for pharmaceutical marketeers to develop their digital content marketing strategies in order to establish their companies as thought leaders and industry experts. -
News High demand: Vetter expands production capacities and services offered at its Austrian site
Pharma service provider further expands offerings for clinical development and manufacturing -
News Novavax will provide adjuvant Matrix-M for vaccine research with 3-year partnership
Novavax, developers behind the Matrix-M adjuvant, have entered into an agreement with the Bill and Melinda Gates Medical Research Institute to provide the adjuvant in preclinical vaccine research.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance